Category: Laser/Light-based Devices
Lumenis prices its initial public offering at $12 per share, meaning it will raise about 20% less from the IPO; shares gain nearly 9% in 1st trading.
Lumenis Ltd. today priced its initial public offering at $12 per share, 20% under the low end of the prior $15-$17 range set by the Israeli maker of medical lasers.
Lumenis shares, trading under the "LMNS" symbol on the NASDAQ exchange, opened up 4.2% at $12.50 today and were fetching $13.05 apiece as of about 11:20 a.m., up 8.8%.
Syneron Medical has a big week with Q4 earnings that beat estimates, a new chief executive and the $15 million acquisition of New Star Lasers and its CoolTouch aesthetic devices.
Israeli device maker Syneron Medical Ltd. (NSDQ:ELOS) made some major moves this month, announcing a new CEO alongside strong Q4 earnings and signing a deal to acquire New Lasers Inc.
Biolase ties the bow on a $5 million private placement with Oracle Investment Management it plans to use to pay down debt.
Biolase (NSDQ:BIOL) said it closed a $5 million private placement with Oracle Investment Management.
The surgical laser maker sold off a little more than 1.9 million shares for $2.57 each, with the deal closing on Feb. 10. The money is expected to go toward paying down its $4.6 million credit facility with Comerica Bank, according to chairman & CEO Federico Pignatelli .
Lumenis says it hopes to bring in up to $106 million in its initial public offering, saying it will price shares in the $15 to $17 range.
Lumenis Ltd. said it plans to sell 6.25 million shares at $15 to $17 apiece in its upcoming initial public offering.
That would bring in between $93.8 million and $106.3 million for the Israeli medical laser maker, which announced the IPO late last year.
Biolitec AG appeals a Massachusetts federal judge's issuance of an arrest warrant for its CEO and a $63 million sanction in its legal war with AngioDynamics.
Florida medical device maker LensAR raises $10 million from 14 unnamed investors, regulatory filings show.
Orlando, Fla.-based cataract surgery technology company LensAR closed an equity funding round with $10 million raised from 14 investors, regulatory documents show.
The fundraising effort, launched in December, was closed yesterday and use of the proceeds was not described, outside of an estimated $370,000 listed in payments to individuals listed as "executive officers, directors or promoters" of the company.
Medical lasers maker Biolase adds 2 new directors to its board and engages Piper Jaffray & Co. as its exclusive financial advisor as it continues to evaluate a potential sale.